Neal Walker - Aclaris Therapeutics President CEO, Director
| ACRS Stock | USD 1.22 0.02 1.61% |
CEO
Dr. Neal Walker is President, Chief Executive Officer, Director of Aclaris Therapeutics, Inc. Dr. Walker cofounded our company and has served as President and Chief Executive Officer and a member of our Board since our inception in July 2012. Dr. Walker cofounded NeXeption, LLC in 2012 and NeXeption II, LLC in 2013. Between 2011 and 2012, Dr. Walker served as a consultant to a number of pharmaceutical companies. Dr. Walker cofounded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, Inc., a dermatologyfocused specialty pharmaceutical company, from 2009 until its acquisition by Allergan, Inc. in 2011. Previously, Dr. Walker cofounded and led a number of life science companies, including Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies, Trigenesis Therapeutics, Inc., a specialty dermatology company, where he served as Chief Medical Officer, and Cutix Inc., a commercial dermatology company. He began his pharmaceutical industry career at Johnson and Johnson, Inc. Dr. Walker is a director of Alderya Therapeutics, Inc., a publicly held biotechnology company, as well as several private biotechnology companies. Dr. Walker received his M.B.A. degree from The Wharton School, University of Pennsylvania, his Doctor of Osteopathic Medicine degree from the Philadelphia College of Osteopathic Medicine and a B.A. degree in Biology from Lehigh University since 2012.
| Age | 48 |
| Tenure | 12 years |
| Address | 701 Lee Road, Wayne, PA, United States, 19087 |
| Phone | 484 324 7933 |
| Web | https://www.aclaristx.com |
Neal Walker Latest Insider Activity
Tracking and analyzing the buying and selling activities of Neal Walker against Aclaris Therapeutics stock is an integral part of due diligence when investing in Aclaris Therapeutics. Neal Walker insider activity provides valuable insight into whether Aclaris Therapeutics is net buyers or sellers over its current business cycle. Note, Aclaris Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Aclaris Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Neal Walker over three months ago Acquisition by Neal Walker of 21222 shares of Aldeyra subject to Rule 16b-3 | ||
Neal Walker over six months ago Payment of 27623 shares by Neal Walker of Aclaris Therapeutics subject to Rule 16b-3 | ||
Neal Walker over six months ago Exercise or conversion by Neal Walker of 9604 shares of Aldeyra subject to Rule 16b-3 | ||
Neal Walker over a year ago Exercise or conversion by Neal Walker of 96150 shares of Aclaris Therapeutics subject to Rule 16b-3 |
Aclaris Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3253) % which means that it has lost $0.3253 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4988) %, meaning that it created substantial loss on money invested by shareholders. Aclaris Therapeutics' management efficiency ratios could be used to measure how well Aclaris Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.47 in 2024. Return On Capital Employed is likely to drop to -0.61 in 2024. At this time, Aclaris Therapeutics' Non Current Assets Total are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 139.1 M in 2024, whereas Other Current Assets are likely to drop slightly above 5.7 M in 2024.Similar Executives
| Found 8 records | CEO Age | ||
| Paul Thomson | Aurora Cannabis | N/A | |
| Keith Kendall | Aquestive Therapeutics | 66 | |
| Daniel Myers | Alimera Sciences | 63 | |
| James Hall | Lifecore Biomedical | 61 | |
| Terry Booth | Aurora Cannabis | 54 | |
| Michael JD | Cronos Group | 37 | |
| Richard Nanula | Lucy Scientific Discovery | 63 | |
| Miguel Martin | Aurora Cannabis | 51 | |
Management Performance
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.33 |
Aclaris Therapeutics Leadership Team
Elected by the shareholders, the Aclaris Therapeutics' board of directors comprises two types of representatives: Aclaris Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aclaris. The board's role is to monitor Aclaris Therapeutics' management team and ensure that shareholders' interests are well served. Aclaris Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aclaris Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Ruffo, CFO CoFounder | ||
| Stuart Shanler, Chief Scientific Officer | ||
| William Humphries, Director | ||
| Stephen Tullman, Chairman of the Board | ||
| Andrew Powell, Independent Director | ||
| Richard Bierly, Director | ||
| Kamil AliJackson, Chief Legal Officer and Assistant Secretary | ||
| David Gordon, Chief Medical Officer | ||
| James Loerop, Chief Officer | ||
| Ketan Patel, Director | ||
| Michael Tung, IR Contact Officer | ||
| Neal DO, President, CoFounder | ||
| Joseph Monahan, Chief Officer | ||
| Gail MD, Chief Officer | ||
| Bryan Reasons, Independent Director | ||
| Brett Fair, Chief Commercial Officer | ||
| Robert Doody, VP Relations | ||
| MD DO, President CoFounder | ||
| Matthew JD, General Secretary | ||
| Albert Cha, Director | ||
| Christopher Molineaux, Director | ||
| Anand Mehra, Director | ||
| Neal Walker, President CEO, Director | ||
| MD Frcp, Pres COO | ||
| Kevin Balthaser, Chief Officer | ||
| Christopher Powala, COO | ||
| Maxine Gowen, Independent Director | ||
| Ian Anderson, Ex RD | ||
| Andrew Schiff, Independent Director | ||
| Jon Jacobsen, Senior Chemistry | ||
| Paul Changelian, VP Biology |
Aclaris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aclaris Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.33 | ||||
| Profit Margin | (2.83) % | ||||
| Operating Margin | (1.35) % | ||||
| Current Valuation | (32.62 M) | ||||
| Shares Outstanding | 70.92 M | ||||
| Shares Owned By Insiders | 2.78 % | ||||
| Shares Owned By Institutions | 95.82 % | ||||
| Number Of Shares Shorted | 4.89 M | ||||
| Price To Earning | (12.14) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aclaris Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aclaris Therapeutics' short interest history, or implied volatility extrapolated from Aclaris Therapeutics options trading.
Pair Trading with Aclaris Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aclaris Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aclaris Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Aclaris Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aclaris Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aclaris Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aclaris Therapeutics to buy it.
The correlation of Aclaris Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aclaris Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aclaris Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aclaris Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Aclaris Stock analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Aclaris Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclaris Therapeutics. If investors know Aclaris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclaris Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 0.448 | Quarterly Revenue Growth 1.266 | Return On Assets (0.33) | Return On Equity (0.50) |
The market value of Aclaris Therapeutics is measured differently than its book value, which is the value of Aclaris that is recorded on the company's balance sheet. Investors also form their own opinion of Aclaris Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aclaris Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclaris Therapeutics' market value can be influenced by many factors that don't directly affect Aclaris Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclaris Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclaris Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclaris Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.